Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BETA Technologies, Inc.BETA · Entity 1930 | Director | June 11, 2026 | June 12, 2026 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director · Chairperson & CEO | October 13, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BETA Technologies, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,213 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 7,142 · Balance 8,213 |
UNITED THERAPEUTICS Corp
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,943 |
Reported balance
After 2026-10-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-10-13 · Exercise / conversion · Acquired 9,500 · Balance 333,943 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 333,304 |
Reported balance
After 2026-10-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-10-13 · Sale · Disposed 639 · Balance 333,304 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 330,964 |
Reported balance
After 2026-10-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-10-13 · Sale · Disposed 2,340 · Balance 330,964 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 329,472 |
Reported balance
After 2026-10-13 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-10-13 · Sale · Disposed 1,492 · Balance 329,472 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 327,965 |
Reported balance
After 2026-10-13 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-10-13 · Sale · Disposed 1,507 · Balance 327,965 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 326,513 |
Reported balance
After 2026-10-13 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-10-13 · Sale · Disposed 1,452 · Balance 326,513 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,883 |
Reported balance
After 2026-10-13 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2026-10-13 · Sale · Disposed 630 · Balance 325,883 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 325,185 |
Reported balance
After 2026-10-13 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2026-10-13 · Sale · Disposed 698 · Balance 325,185 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,683 |
Reported balance
After 2026-10-13 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2026-10-13 · Sale · Disposed 502 · Balance 324,683 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,523 |
Reported balance
After 2026-10-13 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2026-10-13 · Sale · Disposed 160 · Balance 324,523 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 324,443 |
Reported balance
After 2026-10-13 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2026-10-13 · Sale · Disposed 80 · Balance 324,443 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 249,108 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 249,108 F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 45,596 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 45,596 F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 8,902 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 8,902 F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $117.76 · Expires 2027-03-15 | Indirectby Trust | 242,910 |
Reported balance
After 2026-10-13 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-13 · Exercise / conversion · Disposed 9,500 · Balance 242,910 F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026. F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023. F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries. |
| Common StockSEC Table I · non-derivative | Direct | 40,513 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 40,513 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 166 |
Reported balance
Holding disclosure · report date 2026-10-13 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 166 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
F10: This transaction was executed in multiple trades at prices ranging from $549.25 to $550.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11: This transaction was executed in multiple trades at prices ranging from $550.31 to $551.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12: This transaction was executed in multiple trades at prices ranging from $551.37 to $551.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F13: Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F14: Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F15: Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
F16: These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
F17: Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
F2: Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: This transaction was executed in multiple trades at prices ranging from $542.06 to $543.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $543.06 to $544.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $544.08 to $545.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $545.08 to $546.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $546.08 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $547.08 to $547.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $548.12 to $549.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,000 | $53.42 | $160,260.00 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,000 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · derivative · entry 16 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,579 Underlying: Common Stock · 3,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 255 | $212.29 | $54,133.06 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 6 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $211.845 to 212.725. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 526 | $211.20 | $111,093.41 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $210.775 to $211.555. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 503 | $209.96 | $105,608.77 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $209.405 to $210.355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,669 | $208.86 | $348,590.84 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $208.275 to $209.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 47 | $200.06 | $9,402.92 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,083 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $200.06 to $200.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,000 | $53.42 | $160,260.00 |
DisclosureSEC source: 0001415889-22-005659 · form4-05252022_040506.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · CHAIRPERSON & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 29, 2021 Filed Dec 29, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,082 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-031986 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,579 Underlying: Common Stock · 3,082 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 29, 2021 Filed Dec 29, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,082 | $212.49 | $654,894.18 |
DisclosureSEC source: 0001127602-21-031986 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 29, 2021 Filed Dec 29, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,082 | $53.42 | $164,640.44 |
DisclosureSEC source: 0001127602-21-031986 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 27, 2021 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,082 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-031936 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,661 Underlying: Common Stock · 3,082 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 27, 2021 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,082 | $213.31 | $657,421.42 |
DisclosureSEC source: 0001127602-21-031936 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 27, 2021 Filed Dec 27, 2021 21:48 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,082 | $53.42 | $164,640.44 |
DisclosureSEC source: 0001127602-21-031936 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 22:45 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,082 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-031804 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,743 Underlying: Common Stock · 3,082 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 22:45 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,082 | $202.44 | $623,920.08 |
DisclosureSEC source: 0001127602-21-031804 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 22:45 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,082 | $53.42 | $164,640.44 |
DisclosureSEC source: 0001127602-21-031804 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:47 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,082 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-031688 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,825 Underlying: Common Stock · 3,082 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:47 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,082 | $200.00 | $616,400.00 |
DisclosureSEC source: 0001127602-21-031688 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 21:47 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,082 | $53.42 | $164,640.44 |
DisclosureSEC source: 0001127602-21-031688 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001104659-21-144459 · tm2134069-1_4seq1.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,907 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $200.64 | $618,573.12 |
DisclosureSEC source: 0001104659-21-144459 · tm2134069-1_4seq1.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001104659-21-144459 · tm2134069-1_4seq1.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001104659-21-143603 · tm2133880-2_4seq1.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,990 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $200.42 | $617,894.86 |
DisclosureSEC source: 0001104659-21-143603 · tm2133880-2_4seq1.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001104659-21-143603 · tm2133880-2_4seq1.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 22:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-029480 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,073 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 22:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $201.90 | $622,457.70 |
DisclosureSEC source: 0001127602-21-029480 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 22:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001127602-21-029480 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-029127 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,156 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $203.45 | $627,236.35 |
DisclosureSEC source: 0001127602-21-029127 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 15, 2021 Filed Nov 15, 2021 21:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001127602-21-029127 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-028819 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,239 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $200.00 | $616,600.00 |
DisclosureSEC source: 0001127602-21-028819 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F2 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001127602-21-028819 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-028601 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,322 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $200.94 | $619,498.02 |
DisclosureSEC source: 0001127602-21-028601 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 21:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001127602-21-028601 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 4,980 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-028819 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 651,549 F1 · price: Bona fide gift of shares to trusts for the benefit of the reporting person's children, over which the reporting person retains investment and voting authority. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock (Derivative) · Derivative | 3,083 | $0.00 Strike: $53.42 | $0.00 |
DisclosureSEC source: 0001127602-21-028478 · form4.xml · derivative · entry 5 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,405 Underlying: Common Stock · 3,083 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,083 | $200.00 | $616,600.00 |
DisclosureSEC source: 0001127602-21-028478 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,083 | $53.42 | $164,693.86 |
DisclosureSEC source: 0001127602-21-028478 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026044 · form4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 656,529 F1 · kind: Bona fide gift of shares to a 501(c)(3) charitable organization. Reporting person retains retain voting and investment power over the shares while held at the charitable organization. Read SEC document |
| September 17, 2021 Filed Sep 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026044 · form4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130 Read SEC document |
| September 10, 2021 Filed Sep 29, 2021 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 3,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026044 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 658,579 F1 · kind: Bona fide gift of shares to a 501(c)(3) charitable organization. Reporting person retains retain voting and investment power over the shares while held at the charitable organization. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GiftCommon Stock | 1,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028797 · form4.xml · nonDerivative · entry 1 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trusts Disclosed balance after: 662,366 F1 · kind: Bona fide gift of shares to a 501(c)(3) charitable organization. Reporting person retains retain voting and investment power over the shares while held at the charitable organization. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 23:58 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 4,834 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001104659-20-082461 · a4.xml · derivative · entry 7 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,834 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. The transactions on July 9, 2020 represent the final transactions under this trading plan. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 23:58 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 109 | $118.28 | $12,892.52 |
DisclosureSEC source: 0001104659-20-082461 · a4.xml · nonDerivative · entry 4 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. The transactions on July 9, 2020 represent the final transactions under this trading plan. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 23:58 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,664 | $117.39 | $195,333.13 |
DisclosureSEC source: 0001104659-20-082461 · a4.xml · nonDerivative · entry 3 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. The transactions on July 9, 2020 represent the final transactions under this trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $117.19 to $117.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 09, 2020 Filed Jul 9, 2020 23:58 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,061 | $116.81 | $357,556.63 |
DisclosureSEC source: 0001104659-20-082461 · a4.xml · nonDerivative · entry 2 ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,913 F1 · kind: This exercise of options and sale of options is pursuant to a prearranged 10b5-1 trading plan. The trading plan contemplates the exercise and sale of up to 364,834 options with an exercise price of $63.22/share, which were granted in December 2010 and are set to expire at the end of 2020. The transactions on July 9, 2020 represent the final transactions under this trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $116.16 to $117.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.